A sale that was never optional
Synlait Milk completed the $307 million sale of its North Island operations to Abbott on 2 April, handing over its Pokeno manufacturing facility, Auckland blending and canning operations, and a leased warehouse. Of the net proceeds of approximately $283.1 million, some $200 million went straight to repaying bank facilities. The company’s total committed bank facilities halved from $400 million to $200 million.
The language from Synlait’s leadership frames this as strategic simplification. Chair George Adams called it “a defining moment for Synlait”. CEO Richard Wyeth said it would give the company “the space to drive our recovery forward with a focus on where Synlait was founded, in Canterbury”. But the numbers tell a different story. This was not portfolio tidying. This was a company that ran out of room.
How $949 million in revenue produced almost nothing
For the six months ended 31 January 2026, Synlait posted a net loss of $80.6 million, swinging from a $4.8 million profit in the same period a year earlier. Reported EBITDA collapsed from positive $63 million to negative $34.7 million. Revenue actually rose $32.3 million to $949 million. The top line was fine. The problem was that gross profit collapsed $83.9 million to just $3.1 million, and net debt jumped 88 percent to $472.1 million.
A margin of 0.3 percent on nearly a billion dollars of revenue is not a business in difficulty. It is a business with no financial buffer whatsoever.
One plant, one season, no cushion
The cascade began with manufacturing challenges at the Dunsandel plant first reported in July 2025. Those problems forced Synlait to rebuild customer inventory, which created surplus raw milk during peak season. When bulk milk sales fell through, the company had to pivot to whole milk powder, the only product that could be made at short notice. Wyeth explained that whole powder was the only option “without creating significant down time on the dryers, up to 48 hours to change”.
Then whole milk powder prices decreased sharply at the end of 2025, turning a forced production decision into a significant loss.
Wyeth called it “one of the most frustrating seasons in his 18 years in the industry” and described the results as reflecting “a severe lack of optionality, not effort”. That phrase deserves attention. A business with more headroom could have absorbed one bad season at one plant. Synlait could not.
The infant formula trap
Synlait’s core product, advanced nutritional infant formula, is high-margin when things go right and catastrophic when they don’t. Wyeth was blunt about the binary nature of the business: “When it goes well, you get really good results. If it doesn’t go well that product goes straight to stockfeed as opposed to a high value product.”
There is no middle tier. A failed batch of infant formula is not downgraded. It is destroyed or diverted to animal feed. That binary outcome, combined with high leverage, is the structural risk that turned a manufacturing hiccup into an existential crisis.
The $130 million question nobody is asking
The North Island sale has stabilised the balance sheet, but it has not cleaned it. Buried in the completion announcement is a detail most coverage has glossed over: a $130 million shareholder loan from Bright Dairy International Investment Limited that matures on 12 July 2026. That is roughly three months away.
Bright Dairy holds 65.25 percent of Synlait and voted in favour of the North Island sale. Whether it extends, converts, or calls that loan will determine whether Synlait’s recovery roadmap is a plan or a wish. Wyeth has acknowledged that “further work remains to stabilise the business” and that recovery will take “at least 12 months”.
What every capital-intensive business should take from this
Synlait’s three-phase recovery plan is stabilise, simplify, and scale. The company is now concentrated entirely in Canterbury, betting everything on Dunsandel.
The wider lesson is not specific to dairy. When leverage is high, margins are thin, and a single operational problem hits at the wrong point in the commodity cycle, there is no time to adjust. Assets get sold to better-capitalised multinationals like Abbott, processing capacity concentrates into fewer hands, and the company that built the infrastructure ends up renting its own future back from someone else.
Wyeth’s phrase, “severe lack of optionality,” is the most honest description of what happened. Every business owner running a capital-intensive operation should sit with it.
Sources
- Synlait: North Island asset sale completed (2026-04-02)
- Synlait announces FY25 result, entry into agreement to sell North Island assets
- Synlait publishes HY26 result and recovery roadmap
- RNZ: Synlait Milk sells North Island operations to focus on back-to-basics approach
- RNZ: Synlait’s $80.6 million loss after ‘perfect storm’
- NZ Herald: Synlait Milk warns of $77m to $82m half-year loss after Dunsandel issues
- Dairy Business MEA: Synlait Milk Limited reports revenue of US$550M in H1 2026
- StockWireX: SM1 Synlait Milk sells assets for NZ$307M to Abbott